Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 391
- Registration Number
- NCT00577460
- Locations
- 🇮🇳
248.634.91001 Boehringer Ingelheim Investigational Site, Delhi, India
🇭🇺248.634.36005 Boehringer Ingelheim Investigational Site, Györ, Hungary
🇭🇺248.634.36003 Boehringer Ingelheim Investigational Site, Kecskemét, Hungary
Sodium Picosulphate vs. Placebo in Functional Constipation
- Conditions
- Constipation
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 367
- Registration Number
- NCT00576810
- Locations
- 🇩🇪
1062.7.4927 Boehringer Ingelheim Investigational Site, Dortmund, Germany
🇩🇪1062.7.4949 Boehringer Ingelheim Investigational Site, Dresden, Germany
🇩🇪1062.7.4953 Boehringer Ingelheim Investigational Site, Hamburg, Germany
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7376
- Registration Number
- NCT00563381
- Locations
- 🇦🇹
205.389.1020 Boehringer Ingelheim Investigational Site, Feldbach, Austria
🇦🇹205.389.1002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇨🇿205.389.1204 Boehringer Ingelheim Investigational Site, Brno-Kralovo Pole, Czech Republic
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
- Conditions
- Cerebrovascular Accident
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 551
- Registration Number
- NCT00562588
- Locations
- 🇩🇪
9.182.1 Boehringer Ingelheim Investigational Site, Bad Homburg, Germany
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1068
- Registration Number
- NCT00561925
- Locations
- 🇺🇸
1100.1486.0025 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸1100.1486.0041 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸1100.1486.0031 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 112
- Registration Number
- NCT00560508
- Locations
- 🇯🇵
248.610.020 Boehringer Ingelheim Investigational Site, Akita, Akita, Japan
🇯🇵248.610.019 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan
🇯🇵248.610.014 Boehringer Ingelheim Investigational Site, Fuchu, Tokyo, Japan
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1098
- Registration Number
- NCT00558428
- Locations
- 🇳🇱
1235.5.31004 Boehringer Ingelheim Investigational Site, Hoogwoud, Netherlands
🇳🇱1235.5.31003 Boehringer Ingelheim Investigational Site, Musselkanaal, Netherlands
🇳🇱1235.5.31005 Boehringer Ingelheim Investigational Site, Roelofarendsveen, Netherlands
4 Weeks Treatment of Type II Diabetic Patients With BI 44847
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT00558909
- Locations
- 🇩🇪
1224.4.49003 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1224.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
🇩🇪1224.4.49002 Boehringer Ingelheim Investigational Site, Berlin, Germany
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
- Conditions
- Tourette Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT00558467
- Locations
- 🇺🇸
248.644.0012 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸248.644.0026 Boehringer Ingelheim Investigational Site, Bradenton, Florida, United States
🇺🇸248.644.0005 Boehringer Ingelheim Investigational Site, Cambridge, Massachusetts, United States
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BI 10773 high doseDrug: BI 10773 low doseDrug: placebo to BI 10773Drug: BI 10773 medium dose
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 78
- Registration Number
- NCT00558571
- Locations
- 🇩🇪
1245.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
🇩🇪1245.4.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1245.4.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany